Novarel
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Novarel
- Generic name
- GONADOTROPHIN, CHORIONIC
- Manufacturer
- Ferring Pharmaceuticals Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ac6918ff-9dc3-40d9-8619-54b26e4bdfc8
- SPL ID
- dd63b1fd-1f0b-496b-b825-b1f8fb351dbb
- Version
- 41
- Effective date
- 2025-08-27
- Source export date
- 2026-09-28
- Source partition
- 12
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0012-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/663999d0fe1757c1e2cd13a4799d76d875f663e0bc57701092264ebe7febfc18/drug-label-0012-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 06:26:10
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | BLA | 017016 | derived:openfda.application_number |
| application number | BLA017016 | openfda.application_number | |
| brand name | Novarel | openfda.brand_name | |
| generic name | GONADOTROPHIN, CHORIONIC | openfda.generic_name | |
| manufacturer name | Ferring Pharmaceuticals Inc. | openfda.manufacturer_name | |
| ndc | package | 55566-1502-1 | openfda.package_ndc |
| ndc | package | 55566-1700-0 | openfda.package_ndc |
| ndc | product | 55566-1502 | openfda.product_ndc |
| ndc11 | package | 55566150201 | derived:openfda.package_ndc |
| ndc11 | package | 55566170000 | derived:openfda.package_ndc |
| rxcui | 1865295 | openfda.rxcui | |
| rxcui | 310587 | openfda.rxcui | |
| spl id | dd63b1fd-1f0b-496b-b825-b1f8fb351dbb | id | |
| spl set id | ac6918ff-9dc3-40d9-8619-54b26e4bdfc8 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions, and adverse reactions described in the package insert for menotropins. The principal serious adverse reactions during this use are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion; (2) Enlargement of preexisting ovarian cysts or rupture of ovarian cysts with resultant hemoperitoneum; (3) Multiple births, and (4) Arterial thromboembolism. The recommended diluent for reconstitution is Bacteriostatic Water for Injection preserved with benzyl alcohol 0.9%. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants. Anaphylaxis has been reported with urinary-derived HCG products.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS (see WARNINGS ) Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia, pain at the site of injection. Hypersensitivity reactions both localized and systemic in nature, including erythema, urticaria, rash, angioedema, dyspnea and shortness of breath, have been reported. The relationship of these allergic-like events to the polypeptide hormone or the diluent containing benzyl alcohol is not clear.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.